Kaken Pharmaceutical Co Ltd (JP:4521)
:4521
Want to see JP:4521 full AI Analyst Report?
Top Page
Kaken Pharmaceutical Co
(4521)
Select Model
Select Model
Rating:50Neutral
Price Target:
¥4,225.00
▲(13.82% Upside)
Action:Downgraded
Date:05/15/26
The score is primarily constrained by the latest-year operational and cash flow setback (revenue decline, near-breakeven operating results, and negative operating/free cash flow). A very conservative balance sheet provides meaningful downside resilience, while technical signals are mixed-to-weak and valuation is pressured by a high P/E despite a solid dividend yield.
Positive Factors
Conservative balance sheet
Kaken's very low leverage and large equity base provide durable financial flexibility. A conservative balance sheet cushions the company during revenue or cash-flow shocks, supports continued R&D funding or opportunistic M&A, and reduces default risk versus peers over the medium term.
Negative Factors
Sharp revenue and margin decline
A near-20% revenue drop and collapse in operating margins materially weaken the firm's earnings foundation. Sustained top-line pressure reduces internal funding for R&D and commercialization, forcing restructuring or repricing decisions that can impair medium-term growth and competitive positioning.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Kaken's very low leverage and large equity base provide durable financial flexibility. A conservative balance sheet cushions the company during revenue or cash-flow shocks, supports continued R&D funding or opportunistic M&A, and reduces default risk versus peers over the medium term.
Read all positive factors
Kaken Pharmaceutical Co (4521) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥136.33B
Dividend Yield4.16%
Average Volume (3M)164.95K
Price to Earnings (P/E)66.7
Beta (1Y)0.30
Revenue Growth-18.25%
EPS Growth-84.71%
CountryJP
Employees1,135
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)333.12
Shares Outstanding44,139,730
10 Day Avg. Volume176,660
30 Day Avg. Volume164,953
Financial Highlights & Ratios
PEG Ratio-0.87
Price to Book (P/B)1.06
Price to Sales (P/S)2.04
P/FCF Ratio-11.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)44
Revenue Forecast (FY)¥74.16B
Kaken Pharmaceutical Co Business Overview & Revenue Model
Company Description
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychom...
How the Company Makes Money
Kaken Pharmaceutical makes money primarily by selling prescription pharmaceuticals. Revenue is generated when its branded drugs are prescribed by physicians and dispensed to patients, with reimbursement largely occurring under Japan’s national hea...
Kaken Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
86
Very Positive
Cash Flow
32
Negative
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 94.65B | 76.87B | 94.03B | 72.04B | 72.98B | 76.03B |
| Gross Profit | 58.08B | 39.24B | 58.26B | 38.54B | 39.56B | 41.58B |
| EBITDA | 20.34B | 2.43B | 22.02B | 12.57B | 9.40B | 16.38B |
| Net Income | 12.46B | 2.14B | 13.95B | 8.03B | 5.44B | 9.55B |
Balance Sheet | ||||||
| Total Assets | 176.34B | 178.22B | 190.42B | 171.62B | 166.33B | 165.18B |
| Cash, Cash Equivalents and Short-Term Investments | 55.40B | 50.70B | 70.08B | 65.32B | 74.26B | 74.62B |
| Total Debt | 3.85B | 3.85B | 3.85B | 3.85B | 3.85B | 3.85B |
| Total Liabilities | 28.89B | 30.59B | 37.78B | 27.87B | 29.49B | 26.85B |
| Stockholders Equity | 147.45B | 147.62B | 152.63B | 143.75B | 136.26B | 137.75B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -14.07B | 25.64B | 716.00M | 7.27B | 10.35B |
| Operating Cash Flow | 0.00 | -11.08B | 29.78B | 2.58B | 9.25B | 13.34B |
| Investing Cash Flow | 0.00 | 315.00M | -19.65B | -5.85B | -2.63B | -7.89B |
| Financing Cash Flow | 0.00 | -8.84B | -5.37B | -5.66B | -6.99B | -8.13B |
Kaken Pharmaceutical Co Technical Analysis
Negative
3712.00
Price Trends
4103.67
Negative
4100.60
Negative
3900.26
Negative
Market Momentum
-67.88
Positive
26.60
Positive
4.48
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4521, the sentiment is Negative. The current price of 3712 is below the 20-day moving average (MA) of 4047.25, below the 50-day MA of 4103.67, and below the 200-day MA of 3900.26, indicating a bearish trend. The MACD of -67.88 indicates Positive momentum. The RSI at 26.60 is Positive, neither overbought nor oversold. The STOCH value of 4.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4521.
Kaken Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥109.23B | 14.17 | 4.81% | 2.34% | 11.21% | 39.02% | |
58 Neutral | ¥152.56B | 11.38 | 6.70% | 2.48% | 10.28% | 20.78% | |
55 Neutral | ¥169.85B | 18.95 | ― | 2.28% | 6.69% | 6.72% | |
54 Neutral | ¥63.06B | 19.03 | ― | 3.36% | -2.94% | -62.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥136.33B | 66.71 | -2.58% | 4.16% | -18.25% | -84.71% | |
48 Neutral | ¥182.09B | 35.44 | 12.02% | 2.14% | 5.44% | -72.35% |
* Healthcare Sector Average
JP:4521
Kaken Pharmaceutical Co
3,785.00
183.21
5.09%
JP:4547
Kissei Pharmaceutical Co
3,755.00
-301.35
-7.43%
JP:4553
Towa Pharmaceutical Co
3,780.00
662.44
21.25%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,155.00
267.46
9.26%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,156.00
-283.08
-19.67%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
1,719.50
1.55
0.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.